SARS-CoV-2 seroprevalence among workers in a hospital in Madrid
e202110176
Keywords:
SARS-CoV-2, COVID-19, Health personnel, Infection control, Seroprevalence studiesAbstract
Background: The impact of the first wave of the pandemic due to SARS-CoV-2 has been enormous in Spanish hospitals, being Madrid one of the most affected communities. The aim of this study was to analyze the impact of the pandemic on the workers of a hospital located in one of the most affected areas of Madrid (Alcalá de Henares) using a chemiluminescence immunoassay (CLIA).
Methods: We conducted a seroprevalence survey between June 25th and July 31st, 2020, over hospital workers from our institution. This study population was previously analyzed using a diagnostic approach which consisted of PCR and a serologic rapid test. For the present survey, prevalence of IgG antibodies against SARS-CoV-2 was studied using chemiluminescence. We analyzed the prevalence in healthcare workers (HCW) and non-healthcare workers (nHCW). Information about professional category, use of personal protective equipment (PPEs) and previous COVID-19 contacts was collected to determine the risk factors associated with SARS-CoV-2 seropositivity. Comparisons were made using the Mann-Whitney U test (continuous variables) and the two-tailed Fisher’s exact test (categorical variables). Risk factors for seropositivity were analyzed using multivariate logistic regression.
Results: A total of 2,219 workers were included and 847 of them (38.2%) presented IgG antibodies against SARS-CoV-2, being seroprevalence significantly higher for HCW (39.3%) than for nHCW (30.7%, p=0.006). We found no differences regarding positivity rates compared with the first diagnostic approach for symptomatic and asymptomatic workers, or infected workers per professional category. In the multivariate logistic regression analysis, the use of PPE (protective, OR=0.65; 95%CI: 0.48–0.89; p<0.001) and previous contact with COVID-19 patients (risk factor, OR=1.93; 95%CI: 1.37–2.72; p<0.001) were independent factors that were associated with SARS-CoV-2 seropositivity.
Conclusions: More than 38% of our workers presented IgG antibodies against SARS-CoV-2. We found no differences in the positivity rates between diagnostic approaches. The use of PPE (protective) and previous contact with COVID-19 patients (risk factor) were associated with infection.
Downloads
References
Delmas C, Plu-Bureau G, Canouï E, Mouthon L, Meritet J-F. Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4,607 French healthcare workers: Comparison with European countries. Infect Control Hosp Epidemiol. 4 de noviembre de 2020;1-2.
Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. Journal of Clinical Virology. julio de 2020;128:104437.
Fusco FM, Pisaturo M, Iodice V, Bellopede R, Tambaro O, Parrella G et al. COVID-19 infections among Healthcare Workers in an Infectious Diseases specialized setting in Naples, Southern Italy: results of a cross-sectional surveillance study. Journal of Hospital Infection. junio de 2020;S0195670120303066.
Hossain A, Nasrullah SM, Tasnim Z, Hasan MdK, Hasan MdM. Seroprevalence of SARS-CoV-2 IgG antibodies among health care workers prior to vaccine administration in Europe, the USA and East Asia: A systematic review and meta-analysis. EClinicalMedicine. marzo de 2021;33:100770.
Ken-Dror G, Wade C, Sharma SS, Irvin-Sellers M, Robin J, Fluck D et al. SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital. Clin Med. 23 de marzo de 2021;clinmed.2020-1096.
Ebinger JE, Botwin GJ, Albert CM, Alotaibi M, Arditi M, Berg AH et al. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study. BMJ Open. febrero de 2021;11(2):e043584.
Martin C, Montesinos I, Dauby N, Gilles C, Dahma H, Van Den Wijngaert S et al. Dynamic of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk health care workers and hospital staff. Journal of Hospital Infection. junio de 2020;S0195670120303133.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. julio de 2020;S0140673620314835.
Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. diciembre de 2020;11(1):3500.
Krammer F, Simon V. Serology assays to manage COVID-19. Science. 5 de junio de 2020;368(6495):1060-1061.
World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19 [Internet]. [citado 19 de agosto de 2020]. Disponible en: https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19
Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. diciembre de 2020;11(1):4704.
Hanson KE, Caliendo AM, Arias CA, Englund JA, Hayden MK, Lee MJ et al. Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019 (COVID-19): Serologic Testing. Clinical Infectious Diseases. 12 de septiembre de 2020;ciaa1343.
Pérez-García F, Pérez-Zapata A, Arcos N, De la Mata M, Ortiz M, Simón E et al. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among hospital workers in a severely affected institution in Madrid, Spain: A surveillance cross-sectional study. Infect Control Hosp Epidemiol. 29 de octubre de 2020;1-7.
Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings [Internet]. [citado 30 de marzo de 2021]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
Pérez-García F, Pérez-Tanoira R, Romanyk J, Arroyo T, Gómez-Herruz P, Cuadros-González J. Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study. Journal of Clinical Virology. agosto de 2020;129:104473.
Rodriguez A, Arrizabalaga-Asenjo M, Fernandez-Baca V, Lainez MP, Al Nakeeb Z, Garcia JD et al. Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of the COVID-19 pandemic. International Journal of Infectious Diseases. abril de 2021;105:482-486.
Folgueira MD, Munoz-Ruiperez C, Alonso-Lopez MA, Delgado R. SARS-CoV-2 infection in Health Care Workers in a large public hospital in Madrid, Spain, during March 2020. medRxiv (preprint) [Internet]. 11 de abril de 2020 [citado 3 de julio de 2020]; Disponible en: http://medrxiv.org/lookup/doi/10.1101/2020.04.07.20055723
Moncunill G, Mayor A, Santano R, Jiménez A, Vidal M, Tortajada M et al. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. The Journal of Infectious Diseases. 4 de enero de 2021;223(1):62-71.
Barallat J, Fernández-Rivas G, Quirant-Sánchez B, González V, Doladé M, Martinez-Caceres E et al. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. Borrow R, editor. PLoS ONE. 28 de diciembre de 2020;15(12):e0244348.
Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M et al. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain. International Journal of Epidemiology. 12 de enero de 2021;dyaa277.
Red de Vigilancia Epidemiológica. Servicio de Epidemiología. Subdirección General de Epidemiología. Dirección General de Salud Pública. Informe Epidemiológico Vigilancia de COVID-19. Datos acumulados hasta el 10 de mayo de 2020 [Internet]. 2020 [citado 14 de diciembre de 2020]. Disponible en: https://www.comunidad.madrid/sites/default/files/doc/sanidad/epid/informe_historico_hasta_10mayo_covid_actualizado_4-8-2020.pdf
Pérez-Tanoira R, Pérez-García F, Romanyk J, Gómez-Herruz P, Arroyo T, González R et al. Prevalence and risk factors for mortality related to COVID-19 in a severely affected area of Madrid, Spain. medRxiv (preprint) [Internet]. mayo de 2020; Disponible en: http://medrxiv.org/lookup/doi/10.1101/2020.05.25.20112912
Mandrola J. CoViD-19 and PPE: some of us will die because of the shortage (CoViD-19 e dispositivi di protezione individuale: qualcuno di noi morirà per la loro carenza). Recenti Progressi in Medicina. abril de 2020;111(4):183.
Eftekhari A, Alipour M, Chodari L, Maleki Dizaj S, Ardalan M, Samiei M et al. A Comprehensive Review of Detection Methods for SARS-CoV-2. Microorganisms. 22 de enero de 2021;9(2):232.
Fu Y, Pan Y, Li Z, Li Y. The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis. Front Microbiol. 13 de enero de 2021;11:603058.
Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. The Lancet Infectious Diseases. diciembre de 2020;20(12):1390-1400.
Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 8 de octubre de 2020;5(52):eabe5511.
Hanrath AT, Payne BAI, Duncan CJA, van der Loeff IS, Baker KF, Price DA et al. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. Journal of Infection. diciembre de 2020;S0163445320307817.
Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 23 de diciembre de 2020;NEJMoa2034545.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Felipe Pérez-García, Aurora Pérez-Zapata, Naroa Arcos Varela, Manuel de la Mata Herrera, María Ortiz García, Encarnación Simón Ramos, Carlos Calero Barzano, Begoña Clemente García, Laura García Miranda, Lorena Martín Soto, María Ropero Martínez, Rosa María Barrabés Bayascas, Juan Cuadros-González
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
